Large Variation in Provincial Guidelines for Urine Drug Screening During Opioid Agonist Treatment in Canada
Large Variation in Provincial Guidelines for Urine Drug Screening During Opioid Agonist Treatment in Canada
复制标题
DOI：
10.1097/cxa.0000000000000015
复制
发表时间：
2018-06-01
影响因子：
--
通讯作者：
Klimas, Jan
中科院分区：
文献类型：
--
作者：
Moss, Eloise;McEachern, Jasmine;Klimas, Jan
尿药筛查(UDS)通常用于检测或验证自我报告的药物使用情况，特别是在开始和维持阿片类激动剂治疗时。然而，目前还没有公布的加拿大UDS临床实践指南的摘要，也没有衡量不同省份建议使用UDS的一致性。因此，我们对UDS指南进行了政策扫描，检查了加拿大每个省已公布的临床实践指南，并在2017年3月提取了所有相关数据。我们的加拿大指南和政策扫描发现，不同省份对接受阿片类激动剂治疗阿片类药物使用障碍的人的UDS频率建议差异很大。
Urine drug screening (UDS) is commonly used to detect or validate self-reported substance use, particularly when beginning and maintaining opioid agonist therapy. However, there is currently no summary of the published clinical practice guidelines for UDS in Canada, and no measure of the consistency with which different provinces suggest administering UDS. Therefore, we conducted a policy scan of UDS guidelines, examining the published clinical practice guidelines for each Canadian province and extracting all relevant data in March 2017. Our Canadian guideline and policy scan found that UDS frequency recommendations vary greatly among Provinces for persons receiving opioid agonist therapy for opioid use disorder.